Market evolution: Peptide hormones (CN 293719) — 2015–2025
Introduction
CN 293719 covers polypeptide hormones, protein hormones, glycoprotein hormones, their derivatives and structural analogues used primarily as hormones — excluding somatropin and insulin, which have their own codes. This residual category captures a wide and growing range of high-value biopharmaceutical products, including gonadotropins, erythropoietins, and other therapeutic proteins.
Between 2015 and 2025, the EU's extra-EU trade in this product category underwent a dramatic transformation. Export values surged from approximately €780 million to nearly €34.5 billion, while imports grew from €3.6 billion to €22.5 billion. The EU swung from a trade deficit of €2.8 billion to a surplus exceeding €12 billion — a structural reversal of remarkable proportions. This report examines the key dynamics behind this transformation, focusing on the divergence between physical volumes and values, the reorientation of trade geography, and the emergence of Ireland as the dominant force in EU export capacity.
1. A value explosion decoupled from physical volume
1.1 Export values surged while tonnage collapsed
The most striking feature of the 2015–2025 period is the extraordinary divergence between export values and export quantities measured in net mass. EU exports rose from €780 million (2015) to €34.5 billion (2025), an increase of approximately 4,330%. Over the same period, the quantity exported in tonnes actually fell from 702 tonnes to just 55 tonnes — a decline of 92%.
| Metric | 2015 | 2025 | Change |
|---|---|---|---|
| Export value (EUR) | €780 M | €34,543 M | +4,330% |
| Export quantity (tonnes) | 702 t | 55 t | −92% |
| Unit price (EUR/t) | €1.1 M | €631 M | +57,659% |
| Supplementary quantity (GT) | 3,930,346 | 25,990,013 | +561% |
This pattern is characteristic of the biopharmaceutical sector, where high-potency active ingredients are traded in tiny mass volumes at enormous unit prices. The near-disappearance of mass-weighted volume (from 702 t to 55 t) alongside a sixfold increase in supplementary units (gross tonnage) suggests that the products being traded became dramatically more concentrated and valuable per unit of mass — consistent with the shift toward advanced biologic therapies.
1.2 Import values grew strongly, but on expanding physical volumes
EU imports tell a more conventional growth story. Import values rose from €3.6 billion to €22.5 billion (+526%), while tonnage increased from 11.5 to 44.2 tonnes (+283%). Supplementary units (GT) grew from 10.2 million to 38.2 million (+274%). Unlike exports, import volumes broadly kept pace with value growth, though the unit price still rose significantly — from €310 million/t to €502 million/t (+62%).
| Metric | 2015 | 2025 | Change |
|---|---|---|---|
| Import value (EUR) | €3,587 M | €22,462 M | +526% |
| Import quantity (tonnes) | 11.5 t | 44.2 t | +283% |
| Unit price (EUR/t) | €310 M | €502 M | +62% |
| Supplementary quantity (GT) | 10,235,374 | 38,246,148 | +274% |
1.3 EU production scaled massively
The production data from PRODCOM confirms that the EU's domestic manufacturing base for this product category expanded enormously. Production value rose from approximately €1.1 billion to €24 billion (+2,102%), while production quantities measured in gross tonnage surged from 619 million GT to 40 billion GT (+6,365%). This massive scaling of production underpins the EU's transition from a net importer to a net exporter.
2. Geographic reorientation: from Swiss dependence to US-centric trade
2.1 The United States became the dominant trade partner in both directions
The most consequential geographic shift over 2015–2025 was the rise of the United States as the EU's overwhelmingly dominant trade partner for peptide hormones.
On the import side, the US grew from €1.2 billion (2015) to €8.2 billion (2025), an increase of 589%. The US consistently held the largest share of EU imports, though its position fluctuated — the minimum was €143 million in an intermediate year.
On the export side, the growth was even more dramatic: EU exports to the US surged from €76 million to €35.4 billion — an increase of 46,580%. This reflects the enormous expansion of biopharmaceutical manufacturing in the EU (particularly Ireland) for re-export to the US market or for intra-company transfers of high-value biologics.
| Partner | Import 2015 | Import 2025 | Change | Export 2015 | Export 2025 | Change |
|---|---|---|---|---|---|---|
| United States | €1,184 M | €8,161 M | +589% | €76 M | €35,364 M | +46,580% |
| Switzerland | €2,296 M | €1,032 M | −55% | €281 M | €43 M | −85% |
| China | €8 M | €1,444 M | +17,716% | — | — | — |
| India | €1 M | €6 M | +352% | — | — | — |
2.2 Switzerland's role diminished sharply
Switzerland, which was the EU's largest import source in 2015 at €2.3 billion, saw its share decline to €1.0 billion by 2025 (−55%). EU exports to Switzerland also fell dramatically from €281 million to €43 million (−85%). This decline likely reflects shifts in production location and supply chain restructuring, as manufacturing capacity moved into the EU (especially Ireland) and to other global hubs, reducing the transit and processing role that Swiss-based pharma operations had historically played.
2.3 China emerged as a significant new import source
Chinese exports to the EU in this category grew from just €8 million in 2015 to €1.4 billion in 2025 — a 17,716% increase. China's coefficient of variation for import flows was 0.92, indicating relatively high volatility. This emergence mirrors the broader trend of China expanding its biopharmaceutical manufacturing capabilities and competing in peptide hormone production.
3. Ireland's dominance and the EU's structural shift from importer to exporter
3.1 Ireland became the EU's overwhelmingly dominant exporter
The single most important driver of the EU's trade transformation was Ireland. Irish exports of CN 293719 grew from €48 million in 2015 to €50.9 billion in 2025 — an increase of 105,616%. By 2025, Ireland alone accounted for the vast majority of total EU exports in this category.
Ireland's revealed comparative advantage (RCA) stood at 42.78 in 2025, with a normalised RSCA of 0.95 — indicating extreme specialisation. Ireland's production share for this product within its total manufacturing output reached 89.4%, while the product represented only 2.1% of total EU trade in this category by overall share, underscoring how concentrated production became in a single Member State.
| Member State | Export 2015 | Export 2025 | Change | RCA (2025) |
|---|---|---|---|---|
| Ireland | €48 M | €50,879 M | +105,616% | 42.78 |
| Denmark | €32 M | €3,096 M | +9,432% | — |
| Germany | €109 M | €153 M | +41% | — |
| Sweden | €14 M | €57 M | +312% | 0.69 |
| Spain | €6 M | €29 M | +392% | 0.15 |
Denmark also emerged as a major exporter (€32 M → €3,096 M, +9,432%), while more traditional chemical-exporting nations like Germany saw more modest growth (+41%). The data for Denmark's exports largely coincide with the "unspecified territories" partner category (both starting at €4.6 million and reaching €3.1 billion), suggesting that Danish exports may be routed through confidential or aggregated reporting.
3.2 Importing roles shifted within the EU
Among EU Member States, Austria and Italy were the largest importers in 2015 (€2.2 billion and €509 million respectively), but both saw their import values decline by 55% by 2025. Meanwhile, Denmark's imports surged from negligible levels (€301 thousand) to €259 million (+85,925%), and Spain grew from €2.4 million to €54 million. Germany's imports also grew from €118 million to €301 million (+155%).
3.3 The EU flipped from net importer to net exporter
The net import reliance indicator captures this structural reversal most clearly. In 2015, the EU's net import reliance stood at +64.3%, meaning it depended on extra-EU suppliers for nearly two-thirds of apparent consumption. By 2025, this figure had swung to −34.9%, indicating that the EU was now a substantial net exporter — exporting well beyond its own consumption needs.
| Indicator | 2015 | 2025 | Interpretation |
|---|---|---|---|
| Net import reliance | +64.3% | −34.9% | From net importer to net exporter |
| Trade balance (EUR) | −€2,807 M | +€12,081 M | Surplus of €12.1 billion |
| Export propensity | 60.1% | 73.3% | Growing outward orientation |
| Trade intensity | 88.3% | 81.9% | Slight decline in overall trade openness |
Export propensity rose from 60.1% to 73.3%, confirming that the EU's production base became increasingly oriented toward extra-EU markets. Trade intensity (the sum of imports and exports relative to production) declined modestly from 88.3% to 81.9%, as export growth outpaced the need for imports, reflecting growing self-sufficiency.
3.4 Export concentration increased sharply
The Herfindahl-Hirschman Index (HHI) for exports by partner country rose from 3,232 to 9,916 (+207%), indicating a major increase in concentration. This is consistent with the overwhelming dominance of the US as an export destination and the growing weight of Ireland as the exporting hub. Import concentration remained moderate (HHI around 5,000–6,000), suggesting a somewhat more diversified import base, though still highly concentrated among a few key suppliers.
Concentration and specialisation
Conclusion
Over the 2015–2025 period, CN 293719 underwent one of the most dramatic trade transformations visible in EU customs data. The EU moved from a position of significant import dependence (net import reliance of +64%) to becoming a major net exporter (surplus of €12.1 billion), driven overwhelmingly by Ireland's emergence as a global biopharmaceutical manufacturing powerhouse. The divergence between collapsing physical volumes and exploding values in exports reflects the ultra-high value density of modern peptide hormone products.
The geographic reorientation was equally striking: the United States became the dominant partner in both directions, Switzerland's role declined substantially, and China emerged as a significant new import source. Export concentration increased markedly, raising potential questions about supply chain resilience should the Ireland–US axis face disruption.
The volatility data points to persistent instability in several trade corridors, particularly for bilateral flows with the United Kingdom (CV of 2.20 for imports, 1.94 for exports) and China (CV of 0.92 for imports). A notable price shock was detected in EU exports to the UK in 2017, with a unit price shift of +1,542%. These dynamics warrant continued monitoring, particularly given the strategic importance of peptide hormones in healthcare and the EU's now-central role in their global supply.